The emphysema of al-antitrypsin (alAT) deficiency is concep-
increased risk for the development ofemphysema, and a lesser, but definite risk for hepatitis and cirrhosis (1) (2) (3) (4) (5) (6) . In the context of the knowledge that a 1AT provides almost all of the protective screen ofthe lower respiratory tract against the proteolytic enzyme neutrophil elastase (NE), the emphysema ofalAT deficiency is understood to result from insufficient levels of a 1AT in the lower respiratory tract to effectively inhibit the burden of NE in the lungs (7) (8) (9) . Because NE is capable of degrading the connective tissue matrix of the alveolar walls, the chronic burden of free, uninhibited elastase is associated with alveolar wall destruction, i.e., emphysema (1, 3, 5, (8) (9) (10) .
While the deficiency of a I AT in this disorder is understood to result from various mutations in five a I AT coding exons (3, 4) , the destruction ofthe alveolar walls could not occur without the chronic presence of neutrophils within the lung. Interestingly, in previous studies of a 1AT in the epithelial lining fluid of the lower respiratory tract of nonsmoking alAT deficient individuals, we have observed that there are more neutrophils than observed in normals (1 1, 12) . On the basis of these observations, the present study is directed at evaluating the hypothesis that neutrophils accumulate in the alveolar structures of these individuals at least in part because they are attracted by chemotactic signals released by alveolar macrophages. This hypothesis is based on three concepts, including: (a) alveolar macrophages are capable, when activated by surface stimuli, of releasing chemotactic mediators for neutrophils (13) (14) (15) (16) (17) (18) (19) ; (b) alveolar macrophages have surface receptors for neutrophil elastase (20) (21) (22) ; and (c) individuals with a I AT deficiency have insufficient alAT in the lower respiratory tract to inhibit the burden ofNE in the local milieu and thus likely have free NE in the alveolar structures (7, 23) . Putting these concepts together, they lead to a scenario of amplification of normal inflammatory processes, in which free NE resulting from insufficient a 1 AT binds to the NE receptors in alveolar macrophages, causing the macrophages to release mediators with neutrophil chemotactic activity, thus causing an increased number of neutrophils to accumulate in the alveolar structures. Consequently this process would further add to other likely causes of altered alveolar macrophage function in alAT-deficient patients, including cigarrette smoking, airway infection, and the presence of matrix degradation products.
Methods
Study population. The study population consisted of 14 individuals with the Z homozygous form of alAT deficiency, verified by serum alAT levels, isoelectric focusing of serum, and family analysis (24) . There were five females and nine males with an average age of40±5 yr (all data presented as mean±standard error ofthe mean, and all statistical comparisons were made using the two-tailed Student's t test). The average serum alAT level was 4.6 uM (normal 20-48 MM; based on a true laboratory standard; see reference 23 for details). There were six lifelong nonsmokers, and eight former cigarette smokers; the former smokers had stopped an average of 3.5±2.6 yr before the study, with a minimum of 1 yr previously. All individuals had clinical evidence of emphysema based on physical examination, chest x-ray, xenon-133 ventilation scans, technetium-99m-labeled macroaggregated albumin scans and lung function studies (25) (vital capacity 74±15% predicted, forced expiratory volume in 1 s 59±19% predicted, and diffusing capacity for carbon monoxide 65±15% predicted [corrected for hemoglobin and volume]).
For comparison, a population of 11 normal individuals included seven men and four women with an average age of 29±5 yr. All were nonsmokers and none had evidence oflung disease by history, physical examination, chest x-ray, and pulmonary function tests. None were taking any medications. Serum alAT phenotyping demonstrated all were of the MM phenotype (i.e., various combinations of the normal Ml(Val213), Ml(Ala213), M2, and M3 alleles) (3, 4) . As a group, the normals had a serum a lAT level of 39±4 1M.
Quantification of neutrophils in epithelial liningfluid. Bronchoalveolar lavage and cell analysis was carried out in each individual as previously described (26) . The volume of epithelial lining fluid (ELF) recovered was quantified by the urea method and the total number of neutrophils recovered was calculated and expressed per unit volume of ELF recovered (27 dissolved in 250 ,l 30% methanol and applied to a C18 Ultrasphere column (4.6 x 25 cm, Beckman Instruments, Inc., Fullerton, CA). Successive isocratic elution steps were performed at a flow rate of 1 ml/min using two solvent mixtures: solvent A, 90% water/ I0% methanol/0.08% acetic acid; solvent B, 100% methanol.
Step 1 (0-27 min), 45% solvent B; step 2 (27-70 min), 67% solvent B; step 3 (70-100 min), 100% solvent B. Identification of LTB4 in supernate assays was established by coelution with a LTB4 standard (provided by Rokach, J., Merck Frosst, Canada) with the column eluate monitored at 280 nm. Separate chromatographic analyses were performed on five ZZ and five MM individuals.
Direct measurement ofthe concentration ofLTB4 in alveolar macrophage supernates was performed using a radioimmunoassay specific for LTB4 with a lower limit of detectability of 0.08 ng/ml (31, 32) . Alveolar macrophages (2 X 106) were cultured as described above, and the supernates directly analyzed without purification for the presence of immunoreactive LTB4.
Determination that LTB is responsiblefor the chemotactic activity ofalveolar macrophage supernates ofZ homozygotes. To demonstrate that LTB4 was responsible for the majority ofthe neutrophil chemotactic activity present in supernates from ZZ alveolar macrophages, molecular sieve chromatographic analysis was carried out and the peak neutrophil chemotactic activity evaluated by reverse phase HPLC in supernates of three ZZ individuals. Supernate (500 ,ul) from 3 X 106 ZZ alveolar macrophages cultured in HBSS was applied to Superose 12 and Superose 6 molecular sieves (Pharmacia Fine Chemicals, Piscataway, NJ) connected in series. The entire column eluate was collected in l-ml fractions, and each fraction was separately assayed for its chemotactic activity in filter chambers as described above. The peak fractions demonstrating significant chemotactic activity were collected and subsequently analyzed by reverse-phase HPLC as described above.
To positively identify the chemotactic factor induced by elastase, supernates (n = 3) from elastase exposed MM alveolar macrophages and alveolar macrophages from ZZ individuals (n = 3) were individually applied to an affinity chromatography column containing rabbit anti-human LTB4 antibody (supplied by Ford-Hutchinson, A., Merck Frosst, Canada). As a negative control a column containing rabbit anti-human lysozyme was used. Before and after chromatography, the supernates were evaluated for chemotactic activity in filter chambers as described above.
Assessment ofthe ability ofneutrophil elastase to stimulate the release ofLTB by alveolar macrophages. To evaluate the concept that neutrophil elastase might be responsible for the stimulation ofalveolar macrophages to release neutrophil chemotactic activity, purified human neutrophil elastase (100 nM), in RPMI-1640 was added to normal (phenotype MM) alveolar macrophages (30 min, 370) and the supernatants evaluated for neutrophil chemotactic activity as described above.
To determine whether alAT had a modulating effect upon the macrophage elaboration of chemotactic activity in response to neutrophil elastase, aclAT purified from MM human plasma (33) was incubated at concentrations ranging from 50 to 500 nM with 100 nM neutrophil elastase before addition to the MM alveolar macrophages. After a 30-min incubation, the macrophage supernates were collected and assayed for neutrophil chemotactic activity.
Results
Neutrophils in the lower respiratory tract in al-antitrypsin deficiency. Quantification of the lung neutrophil burden by bronchoalveolar lavage demonstrated that ZZ individuals had a greater number ofneutrophils in their alveolar epithelial lining fluid than did normal MM individuals. In this regard, ZZ individuals contained almost threefold more neutrophils in ELF than normals (P < 0.05) (Fig. 1) . In contrast the numbers ofall other cell types (macrophages, lymphocytes, and eosinophils) was similar in both groups, (P > 0.5 all comparisons). Importantly, the increased number of neutrophils was present without evidence ofinfection, or overt inflammation in the form of hyperemia of the airways or increased bronchial mucous. Furthermore, there was no significantly increased number ofbronchial cells in the ZZ lavage fluid compared to normal. Spontaneous release of neutrophil chemotactic activity. Consistent with the observed increase in numbers of neutrophils in ELF ofthe ZZ individuals, when alveolar macrophages recovered from these individuals were cultured in vitro, they spontaneously released significantly greater amounts ofneutrophil chemotactic activity than MM alveolar macrophages, (P < 0.01) (Fig. 2) . Checkerboard analysis of ZZ macrophage supernate demonstrated that the neutrophil migration was due to true chemotactic activity, not chemokinesis (Table I) . Furthermore, the spontaneous release ofneutrophil chemotactic activity by ZZ alveolar macrophages equaled the neutrophil chemotactic factor released by MM alveolar macrophages stimulated in vitro by zymosan (P > 0.5 compared to spontaneous release by ZZ macrophages).
Analysis of alveolar macrophage supernates for LTB4. In the context ofthe knowledge that LTB4 is the major neutrophil chemotactic factor released by human alveolar macrophages, the supernates of ZZ and MM alveolar macrophages cultured in vitro were analyzed for the presence of LTB4. Using a C18 reverse-phase column, we identified an LTB4 standard by its elution time (Fig. 3 A) . Consistent with the comparative lack of neutrophil chemotactic activity present in the supernates of MM alveolar macrophages, no LTB4 was evident on the chromatogram of the MM alveolar macrophage supernates (Fig. 3  B) . In contrast, supernates of ZZ alveolar macrophages contained LTB4, as determined by the presence of a chromatographic peak eluting at the same time as the LTB4 standard (Fig. 3 C) . Consistent with the chromatographic analysis, quantitative analysis of LTB4 production by MM and ZZ alveolar macrophages by radioimmunoassay also demonstrated that the ZZ alveolar macrophages spontaneously released exag- gerated amounts of LTB4 compared with MM alveolar macrophages. In this regard, the ZZ alveolar macrophages released threefold more LTB4 than unstimulated MM macrophages (P < 0.01) (Fig. 4) , an observation consistent with the relative amount of neutrophil chemotactic activity observed in the supernates of the ZZ and MM macrophages (Fig. 2) . Demonstration that LTB4 is the neutrophil chemotacticfactor in ZZ alveolar macrophage supernates. To directly demonstrate that LTB4 was the major chemotactic mediator responsible for the neutrophil chemotactic factor activity found in ZZ alveolar macrophage supernates, combined molecular sieve and reverse-phase HPLC was performed on supernates of unstimulated ZZ macrophages cultured in vitro. When fractions of ZZ macrophage supernate that had been separated according to size on a molecular sieve were analyzed for their neutrophil chemotactic activity, the major peak ofchemotactic activity occurred in the size range between 1,000 and 200 D, a size consistent with that of LTB4 (336 D) (Fig. 5 A) . When these pooled low-molecular weight fractions containing neutrophil chemotactic activity were then analyzed by Cl 8 reverse-phase chromatography, LTB4 was observed (Fig. 5 B) .
Antibody absorption studies definitively identified the chemotactic factor as LTB4. When supernates from elastase exposed MM alveolar macrophages were passed through an affin- ity chromatography column containing antibody against LTB4 the neutrophil chemotactic activity of the supernates was lost.
No such loss of chemotactic activity was seen following supernate exposure to a column containing antibody against human lysozyme (not shown). Similarly, passage of supernates from PiZZ alveolar macrophages through the anti-LTB4 affinity column resulted in loss of the majority of the neutrophil chemotactic activity (Fig. 6) . Neutrophil elastase stimulation of neutrophil chemotactic factor release by MM alveolar macrophages. Consistent with the possibility that it is uninhibited neutrophil elastase in the lower respiratory tract that provides the activation signal to the alveolar macrophages, when MM alveolar macrophages were incubated in vitro with neutrophil elastase, neutrophil chemotactic factor was released in amounts similar to that observed after zymosan incubation (Fig. 7 A) . Furthermore, purified human alAT was able to modulate the neutrophil elastase stimulated release of neutrophil chemotactic factor from MM alveolar macrophages in a dose-dependent manner. In this regard, incubation ofa l AT with neutrophil elastase before its addition to the macrophages resulted in a nearly complete reduction in the stimulation of neutrophil chemotactic factor release by MM alveolar macrophages (Fig. 7 B) . The dose-dependent ability ofa l AT to suppress the effect ofelastase on the MM macrophages is consistent with the known function of alAT to bind to and inactivate neutrophil elastase.
Discussion
The present study suggests that one process which may contribute to the accelerated lung destruction that characterizes alAT deficiency is a chronically increased neutrophil burden in the lower respiratory tract caused by alveolar macrophages releasing neutrophil chemotactic factor LTB4. A likely mechanism which explains this increased release of LTB4 is the binding of free neutrophil elastase by ZZ alveolar macrophages. Consistent with this hypothesis, the ability of elastase to mediate the release of LTB4 does not occur if sufficient alAT is present. These observations suggest a pathologic scenario in which the deficiency of a lAT in the lungs of ZZ individuals results in the presence of free elastase, which then interacts with surface re- ceptors on alveolar macrophages, stimulating the release of LTB4 by the macrophages and consequently the recruitment of still more neutrophils with their burden ofelastase, thus establishing a cycle characterized by a chronically increased lower respiratory tract proteolytic burden. In this context, the imbalance between neutrophil elastase and a 1 AT in the lower respiratory tract of a I AT-deficient individuals is beyond that attributable to the alAT deficiency itself, but is further increased by exaggeration of the neutrophil, and hence neutrophil elastase, burden.
Alveolar macrophage interaction with neutrophil elastase. Neutrophils are present in the lungs of normal individuals in small numbers. A variety of mediators have been identified which likely play a role in neutrophil recruitment into the lungs, including bacterial endotoxin, complement fragments, platelet-activating factor, interleukin-8, the bacterial equivalent of formyl-methionyl-leucyl-phenylalanine, other arachidonic acid metabolites, and one or more polypeptides (13, (16) (17) (18) (19) (34) (35) (36) (37) (38) (39) (40) (41) . The central role of the alveolar macrophage as a mediator of neutrophil accumulation has been clearly documented (42) (43) (44) . Importantly, as the initial cell to encounter foreign substances in the lower respiratory tract, the macrophage is capable ofamplifying the defenses ofthe lower respiratory tract by recruiting neutrophils. It is recognized that LTB4 is the predominant neutrophil chemotactic mediator released by alveolar macrophages (16-18, 39, 40, 42-44) . In this regard, alveolar macrophages synthesize and release LTB4 in response to a number of naturally occurring stimuli including immune complexes, IgE, bacteria, and other phagocytic stimuli such as asbestos (16-18, 35, 39, 44-47) . Neutrophil elastase can now be added to the list ofagents which result in release ofLTB4 by alveolar macrophages.
Although it was not the purpose ofthe present investigation to examine in detail the manner in which neutrophil elastase interacts with the alveolar macrophage to effect LTB4 release, it is known that alveolar macrophages bind and internalize neutrophil elastase, mainly via a low-affinity, high-volume surface receptor (20) (21) (22) . This receptor is not elastase-specific; cathepsin G and lactoferrin are also bound (21) . Bound elastase is internalized by the cell via endocytosis, and is slowly degraded, but under some circumstances may be released in active form from the macrophage (22, 49) . Binding of elastase by its receptor occurs in the absence ofa2-macroglobulin and a 1 -antitrypsin, and is distinct from the macrophage uptake of a2-macroglobulin-protease complexes, which is thought to contribute to the removal of proteases from the extracellular space (20, 50 (54) (55) (56) (57) (58) (59) (60) .
Another role played by alAT in modulating inflammation is its ability to directly act as a chemoattractant after interaction with proteases. After proteolysis by mouse macrophage elastase, a 1 AT undergoes cleavage and structural reorganization, with the generation of a 4.2-kD fragment which is chemoattractive for neutrophils (61) . A similar fragment can be generated after inactivation of human neutrophil elastase by alAT, which also possesses neutrophil chemotactic activity (62) . Therefore, alAT contains latent intrinsic neutrophil chemoattractant properties which become manifest after interaction with its target protease, neutrophil elastase. This intrinsic chemotactic activity of alAT unmasked after interaction with neutrophil elastase may also play a role in recruiting some of the neutrophils observed in the lungs of Z homozygotes, and may also be responsible for the observation in the present study that incubation of fivefold excess alAT with elastase did not completely eliminate chemotactic activity in macrophage supernates, i.e., the residual chemotactic activity may have been due to release of chemotactic fragments from the a 1AT molecule after its cleavage by elastase. The finding of the present study, that a deficiency of alAT serves as the basis for an exaggerated, prolonged inflammatory response characterized by regard, a lAT is not directly active as an inflammatory modulator, aside from its elastase-inhibitory properties. Rather, a lAT acts to interrupt a potential feedback cycle in which free elastase results in the recruitment ofmore neutrophils, hence more elastase, via the interaction of free elastase with macrophages which leads to elaboration of LTB4. By inactivating free elastase, a IAT breaks the cycle; conversely deficiency of alAT may permit amplification and perpetuation of the inflammatory reaction. As with oxidative "switching off" of a lAT, a IAT deficiency may be a "two-edged sword"-beneficial in the face ofmassive infection or other major threat to the organism when the deficiency is temporary and localized, but damaging in the chronic situation such as a lAT deficiency.
